Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850284 | 0.81 | SGK1 (0.40) | AKT2PARP1SGK1TNKSTNKS2 | |
| SCHEMBL19719394 | 0.81 | AKT2 (0.40) | AKT2PARP1SGK1TNKSTNKS2 | |
| SCHEMBL13885 | 0.80 | PARP1 (0.41) | PARP1HRH3CD274 | |
| SCHEMBL13547 | 0.72 | PARP1 (0.37) | PARP1HRH3CD274 | |
| SCHEMBL28153807 | 0.67 | AKT2 (0.51) | AKT2PARP1SGK1TNKSTNKS2 | |
| SCHEMBL28842467 | 0.66 | HRH3 (0.59) | AKT2SGK1HRH3ASIC3TAAR1 | |
| SCHEMBL3789540 | 0.65 | HRH3 (0.52) | AKT2HRH3TAAR1ADRB2NOS3 | |
| SCHEMBL31477842 | 0.64 | HRH3 (0.56) | AKT2SGK1HRH3ASIC3TAAR1 | |
| SCHEMBL17998772 | 0.64 | MAP2K4 (0.39) | PARP1BRAF | |
| SCHEMBL28162272 | 0.64 | HRH3 (0.45) | AKT2PARP1SGK1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | AKT2 3791/4885PARP1 1324/4885SGK1 4128/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | AKT2 3791/4885PARP1 1324/4885SGK1 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.